NetMed, Inc., a developer and marketer of
medical and health-related technologies, announced the commencement
of a multicenter US clinical trial of the PAPNET cervical cancer
detection system as a primary screening test for Pap smears. The
trial is being sponsored by Neuromedical Systems, Inc., developer of
the PAPNET system, which expects to complete the trial in early 1999.
The clinical trial is expected to demonstrate substantially improved
specificity and sensitivity for both conventionally prepared Pap
smears and liquid-based preparations, when compared to current manual
"This is a significant milestone for the technology and our
business," stated David J. Richards, president and CEO of
NetMed. "NSIs worldwide results to date with primary
screening give us optimism that this trial will prove successful.